Lomustine and Bevacizumab in Progressive Glioblastoma
DOI: https://doi.org/10.1056/NEJMoa1707358
2019-10-03
Abstract:Background Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monotherapies. We sought to determine whether the combination would result in longer overall survival than lomustine alone among patients at first progression of glioblastoma. Methods We randomly assigned patients with progression after chemoradiation in a 2:1 ratio to receive lomustine plus bevacizumab (combination group, 288 patients) or lomustine alone (monotherapy group, 149 patients). The methylation status of the promoter of O 6 -methylguanine–DNA methyltransferase ( MGMT ) was assessed. Health-related quality of life and neurocognitive function were evaluated at baseline and every 12 weeks. The primary end point of the trial was overall survival. Results A total of 437 patients underwent randomization. The median number of 6-week treatment cycles was three in the combination group and one in the monotherapy group. With 329 overall survival events (75.3%), the combination therapy did not provide a survival advantage; the median overall survival was 9.1 months (95% confidence interval [CI], 8.1 to 10.1) in the combination group and 8.6 months (95% CI, 7.6 to 10.4) in the monotherapy group (hazard ratio for death, 0.95; 95% CI, 0.74 to 1.21; P=0.65). Locally assessed progression-free survival was 2.7 months longer in the combination group than in the monotherapy group: 4.2 months versus 1.5 months (hazard ratio for disease progression or death, 0.49; 95% CI, 0.39 to 0.61; P<0.001). Grade 3 to 5 adverse events occurred in 63.6% of the patients in the combination group and 38.1% of the patients in the monotherapy group. The addition of bevacizumab to lomustine affected neither health-related quality of life nor neurocognitive function. The MGMT status was prognostic. Conclusions Despite somewhat prolonged progression-free survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with lomustine alone in patients with progressive glioblastoma. (Funded by an unrestricted educational grant from F. Hoffmann–La Roche and by the EORTC Cancer Research Fund; EORTC 26101 ClinicalTrials.gov number, NCT01290939 ; Eudra-CT number, 2010-023218-30 .) Supported by an unrestricted educational grant from F. Hoffmann–La Roche and by the EORTC Cancer Research Fund. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. Dr. Wick reports receiving consulting fees from Merck Sharp & Dohme and Celldex Therapeutics, consulting fees and lecture fees from Bristol-Myers Squibb, grant support and drugs provided for the trial from Roche and Boehringer Ingelheim, and drugs provided for the trial from Apogenix and Pfizer; Dr. Bendszus, receiving grant support from Siemens, Stryker, and Medtronic, consulting fees from Vascular Dynamics, Boehringer Ingelheim, and B. Braun, lecture fees from Teva, grant support and lecture fees from Novartis and Bayer, and grant support, consulting fees, and lecture fees from Codman Neuro and Guerbet; Dr. Taphoorn, receiving consulting fees from F. Hoffmann–La Roche; Dr. Sahm, receiving travel support from Agilent, Illumina, and Roche; Dr. Idbaih, receiving advisory board fees and travel support from F. Hoffmann–La Roche, grant support and travel support from CarThera, advisory board fees from Bristol-Myers Squibb, lecture fees from Cipla, and grant support from Intsel Chimos; Dr. Clement, receiving grant support from AstraZeneca and advisory board fees from Vifor Pharma, LEO Pharma, and Bristol-Myers Squibb, all paid to his institution; Dr. Stupp, receiving travel support from Novocure, receiving advisory board fees from AbbVie, Novartis, Merck (Darmstadt), Merck Sharp & Dohme, Roche, and Celgene, all paid to his institution, and his spouse being a full-time employee of Celgene; Dr. Le Rhun, receiving grant support and lecture fees from Mundipharma and lecture fees from Novartis; Dr. Weller, receiving grant support from Piqur -Abstract Truncated-